Pfizer and biontech sign new global collaboration agreement to develop first mrna-based shingles vaccine

New york and mainz, germany, january 5, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced a new research, development and commercialization collaboration to develop a potential first mrna-based vaccine for the prevention of shingles (herpes zoster virus, or hzv), a debilitating, disfiguring and painful disease that impacts about one in three people in the united states during their lifetime. the collaboration builds on the companies' success in developing the first approved and most widely used mrna vaccine to help prevent covid-19. this is the third collaboration between pfizer and biontech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the covid-19 vaccine collaboration initiated in 2020.
BNTX Ratings Summary
BNTX Quant Ranking